Neurogene INC. (NGNE) — 10-Q Filings
All 10-Q filings from Neurogene INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Neurogene's Losses Widen Amid Increased R&D, Zero Licensing Revenue
— Nov 13, 2025 Risk: high
Neurogene Inc. reported a net loss of $20.95 million for the three months ended September 30, 2025, an increase from $20.22 million for the same period in 2024. -
Neurogene's Q2 Losses Widen Amid Increased R&D Spend
— Aug 11, 2025 Risk: high
Neurogene Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage as a gene therapy company. The com -
Neurogene Inc. Files Q1 2025 10-Q
— May 9, 2025 Risk: low
Neurogene Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Neoleukin Therapeutics, Inc., is in the pharmaceutical prepar -
Neurogene Inc. Files Q3 2024 10-Q
— Nov 18, 2024 Risk: medium
Neurogene Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., is focused on pharmaceutica -
Neurogene Inc. Files Q2 2024 10-Q
— Aug 9, 2024 Risk: medium
Neurogene Inc. filed its 10-Q for the period ending June 30, 2024. The company, formerly known as Neoleukin Therapeutics, Inc., reported its financial status an
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX